Detailed Information

Cited 30 time in webofscience Cited 33 time in scopus
Metadata Downloads

Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis

Authors
Hyun, Jong JinSeo, Yeon SeokYoon, EileenKim, Tae HyungKim, Dong JinKang, Hyun SeokJung, Eun SukKim, Jeong HanAn, HyongginKim, Ji HoonYim, Hyung JoonYeon, Jong EunLee, Hong SikByun, Kwan SooUm, Soon HoKim, Chang DuckRyu, Ho Sang
Issue Date
Apr-2012
Publisher
Blackwell Publishing Inc.
Keywords
cirrhosis; decompensation; entecavir; hepatitis B virus; lamivudine
Citation
Liver International, v.32, no.4, pp.656 - 664
Indexed
SCIE
SCOPUS
Journal Title
Liver International
Volume
32
Number
4
Start Page
656
End Page
664
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/12246
DOI
10.1111/j.1478-3231.2011.02676.x
ISSN
1478-3223
Abstract
Background Suppression of hepatitis B virus (HBV) DNA is more potent, and occurrence of resistant strain is rare with entecavir than lamivudine, but whether these merits result in a more favourable outcome in HBV-related decompensated cirrhosis patients is unclear. Aims To compare virologic response, changes in liver function, clinical course and predictive factors for early mortality after treatment between patients treated with lamivudine and those with entecavir in HBV-related decompensated cirrhosis patients. Methods HBV-related decompensated cirrhosis patients [Child-Turcotte-Pugh (CTP) score ≥ 7] treated with either lamivudine or entecavir were enrolled. Serum HBV DNA levels, CTP score and Model for End-stage Liver Disease (MELD) score were monitored every 3 months. Results Eighty-six patients were enrolled; mean age was 54 ± 11 years, and 63 (73.3%) patients were men; 41 (47.7%) and 45 (52.3%) patients were assigned to the lamivudine group and entecavir group respectively. Although suppression of serum HBV DNA level was more potent in the entecavir group, CTP or MELD scores during the course of treatment did not differ between the two groups. Similarly, 6-month survival rates did not differ between the two groups (95.1 vs 93.2%, P = 0.684). Baseline CTP score and MELD score at 3 months of treatment were significantly associated with 6-month mortality. The 6- and 12-month mortality rates for patients with baseline CTP score ≥11 and MELD score ≥17.5 after 3 months of treatment were 42.9 and 61.9% respectively. Conclusions Although HBV DNA suppression was more potent in the entecavir group than the lamivudine group, early mortality rates did not differ between the two groups. The baseline CTP score and MELD score 3 months after initiating antiviral treatment were significant predictors of early mortality.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Internal Medicine > 1. Journal Articles
1. Basic Science > Department of Biostatistics > 1. Journal Articles
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Byun, Kwan Soo photo

Byun, Kwan Soo
Guro Hospital (Department of Gastroenterology and Hepatology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE